Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new study indicates that the level of adherence required for viral suppression may be lower than previously understood.
For some people with HIV treatment failure, personal difficulties with adherence may be at the root of the problem.
A long-term study sought to determine which factors help predict low adherence among young people with the virus.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
Generalized anxiety disorder is associated with lower rates of HIV treatment, adherence to treatment and viral suppression.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
A $3.5 million grant to the University of Illinois at Chicago will help researchers find out.
Changes include new information about risks associated with dolutegravir during pregnancy and removal of older drugs owing to toxicities.
The high cost of antiretrovirals may get passed along to consumers through co-pays, co-insurance or deductibles.
A look at 2009 to 2014 data found that those in care for HIV saw a considerable fall in treatment deferrals.
This cheap test could be a good way to assess adherence, unless those who adhere poorly fudge the result by taking a dose before a visit.
The viral suppression rate in this group was considerably higher than that seen in the same clinics a decade before.
A lesson that adherence to HIV medication is a reality, even for long-term survivors
December 2018 Survey
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.